American Century Companies Inc. Has $104.63 Million Position in Alkermes plc $ALKS

American Century Companies Inc. lifted its holdings in Alkermes plc (NASDAQ:ALKS) by 5.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 3,657,223 shares of the company’s stock after purchasing an additional 191,549 shares during the quarter. American Century Companies Inc. owned about 2.22% of Alkermes worth $104,633,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. JPMorgan Chase & Co. lifted its stake in Alkermes by 488.6% in the first quarter. JPMorgan Chase & Co. now owns 5,234,995 shares of the company’s stock valued at $172,860,000 after buying an additional 4,345,523 shares in the last quarter. Nuveen LLC bought a new stake in Alkermes in the 1st quarter valued at $66,689,000. Acadian Asset Management LLC boosted its stake in Alkermes by 2,422.0% in the 1st quarter. Acadian Asset Management LLC now owns 881,827 shares of the company’s stock worth $29,100,000 after purchasing an additional 846,861 shares during the period. Driehaus Capital Management LLC bought a new position in Alkermes during the 1st quarter worth about $26,179,000. Finally, MetLife Investment Management LLC increased its holdings in Alkermes by 487.0% during the 1st quarter. MetLife Investment Management LLC now owns 567,621 shares of the company’s stock worth $18,743,000 after purchasing an additional 470,926 shares in the last quarter. 95.21% of the stock is owned by institutional investors.

Insider Transactions at Alkermes

In other news, EVP Craig C. Hopkinson sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $30.38, for a total value of $273,420.00. Following the completion of the sale, the executive vice president directly owned 69,740 shares of the company’s stock, valued at $2,118,701.20. This trade represents a 11.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 4.40% of the stock is owned by corporate insiders.

Alkermes Trading Up 2.8%

NASDAQ ALKS opened at $28.99 on Wednesday. The firm has a market capitalization of $4.79 billion, a P/E ratio of 14.35, a price-to-earnings-growth ratio of 1.70 and a beta of 0.53. The firm’s fifty day moving average price is $30.21 and its two-hundred day moving average price is $29.45. Alkermes plc has a 1 year low of $25.17 and a 1 year high of $36.45.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Tuesday, October 28th. The company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.08. Alkermes had a net margin of 22.27% and a return on equity of 21.81%. The company had revenue of $394.19 million for the quarter, compared to analyst estimates of $355.23 million. During the same period in the previous year, the business earned $0.73 EPS. Alkermes’s revenue for the quarter was up 4.3% compared to the same quarter last year. Alkermes has set its FY 2025 guidance at 1.360-1.470 EPS. On average, research analysts anticipate that Alkermes plc will post 1.31 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ALKS has been the topic of a number of research reports. Zacks Research lowered Alkermes from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 20th. Truist Financial lifted their target price on Alkermes from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, November 17th. JPMorgan Chase & Co. upped their price target on Alkermes from $34.00 to $35.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 9th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Alkermes from $55.00 to $45.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. Finally, Wall Street Zen lowered shares of Alkermes from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 9th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $44.69.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.